Nov 2
Registration statement
S-3ASR
Registration statement
ALLO · Allogene Therapeutics, Inc. · Documents
$0.84
+0.01 (+1.41%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$290.58M
Shares
346.47M
Volume · Nov 13
11.66M
Avg daily vol (3M)
7.37M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
Oct 6
Current report
8-K
Other events
Sep 21
Current report
8-K
Events of Sep 15
Other events
Aug 9
Earnings call
Q2 2022 earnings call
Aug 9
Current report
8-K
Financial results
Aug 9
Quarterly report
10-Q
FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Revenue $86K
▲ 95.5%
Net loss $74.79M
Diluted EPS -$0.52
Jul 20
Tender offer
SC TO-I/A
Tender offer
Jul 12
Current report
8-K
Events of Jul 8
Director or officer change, or executive pay
Jul 12
Tender offer
SC TO-I/A
Tender offer
Jun 21
Tender offer
SC TO-I
Tender offer
Jun 17
Current report
8-K
Events of Jun 15
Shareholder vote results
May 4
Earnings call
Q1 2022 earnings call
May 4
Current report
8-K
Financial results
May 4
Quarterly report
10-Q
FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Revenue $61K
▼ 99.8%
Net loss $79.85M
Diluted EPS -$0.56
Apr 26
Proxy statement
DEF 14A
Meeting Jun 15, 2022
Proxy statement
Apr 26
Proxy statement
DEFA14A
Proxy statement
Apr 14
Tender offer
SC TO-C
Tender offer
Apr 14
Proxy statement
PRE 14A
Meeting Jun 15, 2022
Proxy statement
Feb 23
Earnings call
Q4 2021 earnings call
Feb 23
Current report
8-K
Financial results
Feb 23
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $38.49M
Net loss $257.01M
Diluted EPS -$1.89
2021
Dec 15
Current report
8-K
Events of Dec 10
Entered into a material agreement, Other events
Nov 4
Earnings call
Q3 2021 earnings call
Nov 4
Current report
8-K
Financial results
Nov 4
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $49K
Net loss $78.19M
Diluted EPS -$0.57
Oct 7
Current report
8-K
Other events
Aug 4
Earnings call
Q2 2021 earnings call
Aug 4
Current report
8-K
Financial results
Aug 4
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $44K
Net loss $70.94M
Diluted EPS -$0.53
Aug 2
Current report
8-K
Events of Jul 30
Director or officer change, or executive pay
Jun 15
Current report
8-K
Events of Jun 10
Shareholder vote results
May 20
Current report
8-K
Events of May 18
Director or officer change, or executive pay
May 19
Current report
8-K
Other events
May 5
Earnings call
Q1 2021 earnings call
May 5
Current report
8-K
Financial results
May 5
Quarterly report
10-Q
FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Revenue $38.35M
Net loss $33.02M
Apr 22
Proxy statement
DEF 14A
Meeting Jun 10, 2021
Proxy statement
Apr 22
Proxy statement
DEFA14A
Proxy statement
Feb 25
Earnings call
Q4 2020 earnings call
Feb 25
Current report
8-K
Financial results
Feb 25
2020
Dec 15
Current report
8-K
Events of Dec 14
Entered into a material agreement
Dec 7
Current report
8-K
Events of Dec 5
Other events
Nov 4
Earnings call
Q3 2020 earnings call
Nov 4
Current report
8-K
Financial results
Nov 4
Oct 26
Current report
8-K/A
Events of Jun 5
Shareholder vote results
Aug 5
Earnings call
Q2 2020 earnings call
Aug 5
Current report
8-K
Financial results
Aug 5
Showing 101–150 of 161 documents
Key facts
CIK
1737287
CUSIP
019770106
13F (30d)
158 filings
136 filers
Visit website
Investor relations